Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
2.020
-0.060 (-2.88%)
At close: May 29, 2026, 4:00 PM EDT
2.040
+0.020 (0.99%)
After-hours: May 29, 2026, 5:41 PM EDT
Actuate Therapeutics Employees
Actuate Therapeutics had 12 employees as of December 31, 2025. The number of employees increased by 2 or 20.00% compared to the previous year.
Employees
12
Change (1Y)
2
Growth (1Y)
20.00%
Revenue / Employee
n/a
Profits / Employee
-$1,794,715
Market Cap
48.33M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 12 | 2 | 20.00% |
| Dec 31, 2024 | 10 | 5 | 100.00% |
| Sep 30, 2024 | 11 | 6 | 120.00% |
| Jun 30, 2024 | 11 | - | - |
| Mar 31, 2024 | 10 | - | - |
| Dec 31, 2023 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Metagenomi Therapeutics | 119 |
| Xilio Therapeutics | 76 |
| Mereo BioPharma Group | 39 |
| Quantum BioPharma | 17 |
| MiNK Therapeutics | 15 |
| Cingulate | 14 |
| Hyperion DeFi | 9 |
ACTU News
- 11 days ago - Actuate Therapeutics price target lowered to $5 from $6 at Lucid Capital - TheFly
- 18 days ago - Actuate Therapeutics receives FDA clearance for oral elraglusib study - TheFly
- 18 days ago - Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program - GlobeNewsWire
- 20 days ago - Analysts see 200%+ upside in these 3 high-risk stocks: here's why? - Invezz
- 23 days ago - Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors - GlobeNewsWire
- 4 weeks ago - Actuate Therapeutics management to meet with B. Riley - TheFly
- 5 weeks ago - Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - Reuters
- 6 weeks ago - Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewsWire